Meta-Analysis of Antidepressant Augmentation: Piling on in the Absence of Evidence

Yury, Craig A.; Fisher, Jane E.; Antonuccio, David O.; Valenstein, Marcia; Matuszak, Jeremy
November 2009
Ethical Human Psychology & Psychiatry;2009, Vol. 11 Issue 3, p171
Academic Journal
Background: Treatment of depression with a single pharmaceutical agent often does not work, and several agents may be tried or combined to increase efficiency. Augmentation involves the addition of one or more medications to an existing antidepressant monotherapy to enhance mood and overall antidepressant response. Approximately 22% of individuals with unipolar depression are prescribed augmentation strategies. This study examined the effectiveness of augmentation strategies. Methods: A Medline search of studies published before January 1, 2007 was conducted to assess the extent of published data on the most frequently prescribed augmentation strategies. Studies with completed original data, sufficient efficacy data, and participants diagnosed with unipolar depression were included. Letters to the editor, preliminary data, data only presented at conferences, and small uncontrolled case reports were excluded. Results: 13 studies contained sufficient data to calculate an effect size. Mean estimated effect size of all 13 studies calculated with random effects was 0.1782 with a 95% confidence interval of -0.2513-0.6076. Conclusions: There are minimal published data examining antidepressant augmentation, and augmentation is a minimally effective treatment option.


Related Articles

  • Smoking Cessation Interventions for Patients with Depression: A Systematic Review and Meta-analysis. Gierisch, Jennifer; Bastian, Lori; Calhoun, Patrick; McDuffie, Jennifer; Williams, John // JGIM: Journal of General Internal Medicine;Mar2012, Vol. 27 Issue 3, p351 

    OBJECTIVES: We conducted a systematic literature review of smoking cessation interventions for patients with histories of depressive disorders or current significant depressive symptoms. We examined the comparative effectiveness of smoking cessation strategies on abstinence rates, differential...

  • Male depression A review of gender concerns and testosterone therapy. Orengo, Claudia A.; Fullerton, Ginny; Tan, Robert // Geriatrics;Oct2004, Vol. 59 Issue 10, p24 

    Identifies possible secondary medical abnormalities that may either accompany or derive from the depressed mood and pharmacologic treatments that have been shown to be more efficacious in aging men. Benefit of testosterone augmentation; Psychological, social factors; Biological factors;...

  • The Clinical Neuroscience of Post Stroke Depression. Haroon, Ebrahim; Kumar, Anand // Current Neuropharmacology;Oct2004, Vol. 2 Issue 4, p353 

    Post stroke depression or PSD is believed to occur in ten to forty percent of all patients who survive stroke. These mood disturbances overlap with primary major depressive disorder in terms of symptom profile, natural history and response to antidepressant medications. Cognitive changes,...

  • The Human Cost of Not Achieving Full Remission in Depression. McIntyre, Roger S.; O'Donovan, Claire // Canadian Journal of Psychiatry;Mar2004 Supplement, Vol. 49, p10S 

    Depression is among the most disabling and costly illnesses in the world. Despite good short-term efficacy outcomes in the treatment of depression, long-term outcomes remain disappointing. Depression continues to be missed or underdiagnosed and undertreated, and comorbidities are frequently not...

  • Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Kato, M.; Serretti, A. // Molecular Psychiatry;May2010, Vol. 15 Issue 5, p473 

    This systematic review summarizes pharmacogenetic studies on antidepressant response and side effects. Out of the 17 genes we reviewed, 8 genes were entered into the meta-analysis (SLC6A4, HTR1A, HTR2A, TPH1, gene encoding the β-3 subunit, brain-derived neurotrophic factor (BDNF), HTR3A and...

  • Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Molendijk, M L; Spinhoven, P; Polak, M; Bus, B A A; Penninx, B W J H; Elzinga, B M // Molecular Psychiatry;Jul2014, Vol. 19 Issue 7, p791 

    Meta-analyses, published in 2008-2010, have confirmed abnormally low serum brain-derived neurotrophic factor (BDNF) concentrations in depressed patients and normalization of this by antidepressant treatment. These findings are believed to reflect peripheral manifestations of the neurotrophin...

  • Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review. Zimovetz, Evelina A.; Wolowacz, Sorrel E.; Classi, Peter M.; Birt, Julie // Cost Effectiveness & Resource Allocation;2012, Vol. 10 Issue 1, p1 

    Background: Decision makers in many jurisdictions use cost-effectiveness estimates as an aid for selecting interventions with an appropriate balance between health benefits and costs. This systematic literature review aims to provide an overview of published cost-effectiveness models in major...

  • JAMA analysis stirs debate. M. I. // Medical Marketing & Media;Feb2010, Vol. 45 Issue 2, p18 

    The article reports on the meta-analysis which found that antidepressants are useful for patients with severe symptoms of depression but do not work any better than placebo in mild cases.

  • KEY DEVELOPMENTS DEPRESSION.  // Update;11/6/2003, Vol. 67 Issue 9, p482 

    The article focuses on the latest developments and their practical implications for general practitioners. A meta-analysis has shown that low-dose TCAs are more likely than placebo to improve depression after 1 and 2 months' treatment. The treatment of depression with low-dose TCAs may be...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics